Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin

Objectives: Effective treatment with direct-acting antiviral drugs against hepatitis C virus (HCV) is a medical need in cirrhotic HIV–HCV co-infected patients. Methods: This study investigated the plasma levels of daclatasvir (DCV) and ribavirin (RBV) in HIV–HCV co-infected subjects treated with DCV...

Full description

Bibliographic Details
Main Authors: Saverio G. Parisi, Arianna Loregian, Samantha Andreis, Giulio Nannetti, Silvia Cavinato, Monica Basso, Renzo Scaggiante, Federico Dal Bello, Lorenzo Messa, Anna Maria Cattelan, Giorgio Palù
Format: Article
Language:English
Published: Elsevier 2016-08-01
Series:International Journal of Infectious Diseases
Subjects:
Daclatasvir
HIV–HCV patients
Therapeutic drug monitoring
Virological failure
Population-based sequencing
Mutation
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971216311055

Internet

http://www.sciencedirect.com/science/article/pii/S1201971216311055

Similar Items